Farmakoloģijas katedras pētnieki piedalās vairākos nacionālas nozīmes un starptautiskos projektos, kas ir vērsti uz neiroloģisko saslimšanu (šizofrēnijas, Alcheimera, Pārkinsona slimības un insulta) mehānismu izpēti, kas nākotnē palīdzētu izstrādāt jaunas ārstēšanas stratēģijas.

Aktuālie projekti

Projekta ietvaros notiks mikrogliālās aktivācijas lomas izpēte komplementa C4-stratificētos šizofrēnijas pacientos un peļu C4 pārmērīgas ekspresijas modelī.

  • Projekta numurs: 1.1.1.5/ERANET/20/01
  • Konsorcija koordinators: Ryad Tamouza (FR)
  • Konsorcija partneru projektu dalībvalstu vadītāji: Benoît Zuber (CH) Corentin Le Magueresse (FR) Martin Fuhrmann (DE) un Baiba Jansone (LV)
  • Projekta realizācijas termiņš: 2020-2022
  • Projekta numurs: lzp-2018/1-0275
  • Projekta zinātniskā vadītāja: Baiba Jansone
  • Projekta realizācijas termiņš: 2018-2021.

Detalizēta informācija

Projekta ietvaros notiks daudzpakāpju sinaptiskās disfunkcijas izpēte insulta modeļos.

  • Projekta numurs: ES RTD/2018/29
  • Konsorcija koordinators: Valentin U. Nägerl (FR)
  • Konsorcija partneru projektu dalībvalstu vadītāji: Nikolaus Plesnila (DE), Jérôme Badaut (FR), Leszek Kaczmarek (PL), Javier Defelipe (ES) un Baiba Jansone (LV)
  • Projekta realizācijas termiņš: 2018-2021.

Detalizēta informācija

  • Projekta numurs: 2213
  • Projekta vadītājs: Vladimirs Piļipenko
  • Projekta realizācijas termiņš: 2018-2020.

Īstenotie projekti

EEZ un Norvēģijas finanšu instrumenta projekts “Dažādu beta-amiloīda peptīdu sekvenču efekti: fokuss uz īso peptīdu pielietojuma iespējām demences terapijā”.

  • Projekta numurs: NFI/R/2014/023
  • Projekta vadītājs: Baiba Jansone
  • Projekta realizācijas termiņš: 2015.-2017.


ERAF finansētais projekts “Hronisku brūču dzīšanu veicinošas medicīnas ierīces
izstrāde”

  • Projekta numurs: 2DP/2.1.1.1.0/14/APIA/VIAA/046
  • Projekta izpildītāji MF: Baiba Jansone, Zane Dzirkale
  • Projekta realizācijas termiņš: 2014.-2015.
     

EEZ un Norvēģijas finanšu instrumenta stipendiju projekts “Enhancing human capital and knowledge in health science by institutional cooperation and mobility between the University of Latvia and three Norwegian universities”

  • Projekta numurs: EEZ/NFI/S/2015/019
  • Projekta koordinators ar Oslo Universitāti: Baiba Jansone
  • Projekta realizācijas termiņš: 2015.-2016.
     

EEZ un Norvēģijas finanšu instrumenta stipendiju projekts “Pētniecība un stipendijas” divpusējās sadarbības fonda sagatavošanas vizīšu projekta ieviešana”

  • Projekta numurs: NOR-S-PV2014/008
  • Projekta koordinators ar Oslo Universitāti: Baiba Jansone
  • Projekta realizācijas termiņš: 2015.
     

LU finansēts projekts “Mirstības izpēte dažāda vecuma pacientu grupās un jaunu struktūru izpēte neirodeģeneratīvo saslimšanu ārstēšanā”

  • LU Projekta numurs: ZD2014/AZ78
  • Projekta vadītājs: Ingrīda Rumba-Rozenfelde
  • Projekta realizācijas termiņš: 2014.-2015.

“Pharma and Chemistry Competence Centre of Latvia finansētais projekts “Egles skuju izoprēnspirtu bioloģiskās darbības pētījumi slimību patoloģiju modeļos”

  • Projekta numurs: KC/2.1.2.1.1/10/01/006
  • Projekta realizācijas termiņš: 2013.-2014.
     

LZP finansēts projekts “Multiheterociklu ķīmijas attīstīšana jaunu bioloģiski aktīvu vielu iegūšanai”

  • Projekta numurs: 10.0030
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2009.-2013.
     

Eiropas Sociālā fonda (ESF) finansēts projekts “Neiroimūnās regulācijas iespējas neirodeģeneratīvo slimību ārstēšanā ar jauna tipa priviliģētām struktūrām”

  • Projekta numurs: 2009/0217/1DP/1.1.1.2.0/09/APIA/VIAA/031
  • Projekta vadītāja: Baiba Jansone
  • Projekta realizācijas termiņš: 2010.-2012.


LU finansēts projekts “Neirogliālās šūnas kā neiroprotektīvo vielu darbības mērķis”

  • Projekta numurs: LU-2009/ZP-94
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš 2009.-2012.


LZP finansēts projekts “Uz mitohondrijiem mērķētu mazo molekulu reģeneratīvie efekti neirodeģenerācijas modeļos”

  • Projekta numurs: Z-6173-840
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2009.-2012.

LU finansēts projekts “Uz mitohondrijiem mērķētās farmakoterapijas efektivitāte multiplās sklerozes modelī”

  • Projekta numurs: 2008/ZP-28
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš 2007.-2008.
     

A/S “Olainfarm” un LU pētniecības projekts “Neiromidīna pētījumi diabēta neiropātijas modelī žurkām”

  • Projekta numurs: 2008/2467
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2008.


LZP finansēts projekts “Jaunas stratēģijas anti-HIV terapijas izraisīto neiro- un kardiomiopātiju protekcijā”

  • Projekta numurs: 05.1418
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2005.-2008.
     

EU COST projekts “Targeting of taurine and its analogues to protect against oxidative stress”

  • Projekta numurs: D34
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2005.-2008.
     

EU COST projekts “Design for Sustainable and/or Green Biologically Important Agents”

  • Projekta numurs: D29
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2004.-2007.


A/S „Grindeks” un LU Pētniecības projekts “Mildronāta terapeitiskās/protektīvas aktivitātes novērtējums dažādu klašu anti-HIV preparātu kardio-, neiro- un hepatotoksicitātes modeļos”

  • Projekta numurs: 2362
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2007.


A/S „Grindeks” un LU Pētniecības projekts “Cerebrokrasta jauno analogu neiroprotektīvās aktivitātes pētījumi in vivo”

  • Projekta numurs: 2376
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2007.


A/S „Grindeks” un LU Pētniecības projekts “Mildronāta terapeitiskās efektivitātes noteikšana stavudīna izraisīto perifēro neiropātiju modelī žurkām”

  • Projekta numurs: 2377
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2007.


Sadarbības līgums starp A/S „Grindeks”, LU un Latvijas Organiskās sintēzes institūtu “Mildronāta protektīvie efekti anti-HIV terapijas izraisītajās kardio- un neiropātijās”

  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2006.


LU finansēts projekts “Stresa izraisītie neiroķīmisko procesu traucējumi un to protekcijas/reversijas iespējas: mitohondriji kā mērķis”

  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2006.

LU finansēts projekts “Atkarību izraisošo vielu melanokortīnerģisko signālmehānismu pētījumi”

  • Projekta numurs: 2005/7-LU
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2004.-2005.


EU projekts “MedNatNet”

  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2003.-2004.


EU COST projekts “Novel Peptidomimetic Type Substances with Neuroprotective Properties”

  • Projekta numurs: D13
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2001.-2004.


Howard Hughes Medical Institute finansēts projekts “Pharmacological Studies on Melanocortin Receptor Subtypes”

  • Projekta numurs: 75195-542601
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1995.-2000


LZP finansētais projekts “Melanokortīnu kā vielu atkarības regulātoru izraisītie neiroķīmiskie un uzvedības procesi”

  • Projekta numurs: 01.0037
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2001.-2004.


LU Zinātniskās un tehniskās kooperācijas ar Upsalas Universitāti finansiālās palīdzības grants

  • Projekta numurs: 1874
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 2000.-2002.


LZP finansēts projekts “Aminoskābes saturošu peptidomimētiķu neirotrofās un antineirotoksiskās darbības mehānismu pētījumi”

  • Projekta numurs: 96.698
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1997.-2000.

EU COPERNICUS pētniecības projekts “Investigation and Elaboration of Novel Chiral Drugs for Biotechnological Procedures”

  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1995.-1997.


KIRT finansētais projekts “Neuroactive Amino Acid Containing Peptidomimetics: Focus in the Neurotransmitter Mechanisms”

  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1995.-1996.
     

LZP finansēts projekts “Jauna tipa kognitīvo funkciju stimulējošas vielas: uzvedības un intracelulāro procesu pētījumi”

  • Projekta numurs: 93.439
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1994.-1996.


KIRT finansēts projekts “Peptide-mimicking Substances: Role of the “Free” and “Crypto” Amino Acids in Memory Improving Activity”

  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1994.


LZP finansētais projekts “Nervu un miokarda šūnu funkcionālo mehānismu pētījumi hipoksijas, stresa, novecošanās un citos aversīvos apstakļos un attiecīgo endogēno un eksogēno korektoru meklējumi”

  • Projekta numurs: 90.428
  • Projekta vadītājs: Vija Kluša
  • Projekta realizācijas termiņš: 1991.-1993.

Publikācijas

Farmakoloģijas katedras darbinieku pētījumu rezultāti tiek publicēti starptautiski citējamos žurnālos neirozinātnē, tostarp arī augstas raudzes žurnālos ar Q1 radītāju, piemēram, Basic Clinical Pharmacology and Toxicology (H=80), BMC Neuroscience (H=86), European Journal of Pharmacology (H=167), Neuropharmacology (H=150), Pharmacological Research (H=118), PLoS ONE (H=268).

  • Narbute K, Pilipenko V, Pupure J, Dzirkale Z, Jonavičė U, Tunaitis V, Jansone B, Klusa V, Pivoriūnas A. Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase Expression in the Substantia Nigra and Striatum of the 6-Hydroxydopamine-Treated Rats. Stem Cells Transl Med, 2019, 8(5), 490-9. https://doi.org/10.1002/sctm.18-0162
  • Pilipenko V, Narbute K, Amara I, Trovato A, Polimeni A, Pupure J, Poikans J, Bisenieks J, Calabrese V, Jansone B, Klusa V. GABA-containing compound gammapyrone protects against brain impairments in Alzheimer's disease model male rats and prevents mitochondrial dysfunction in cell culture. J Neurosci Res, 2019, 97(6), 708-26. https://doi.org/10.1002/jnr.24396
  • Pilipenko V, Narbute K, Pupure J, Rumaks J, Jansone B, Klusa V. Neuroprotective action of diazepam at very low and moderate doses in Alzheimer's disease model rats. Neuropharmacol, 2019, 144, 319-26. https://doi.org/10.1016/j.neuropharm.2018.11.003
  • Pilipenko V, Narbute K, Beitnere U, Rumaks J, Pupure J, Jansone B, Klusa V. Very low doses of muscimol and baclofen ameliorate cognitive deficits and regulate protein expression in the brain of a rat model of streptozocin-induced Alzheimer's disease. Eur J Pharmacol, 2018, 818, 381-99. https://doi.org/10.1016/j.ejphar.2017.11.012
  • Sike Á, Wengenroth J, Upīte J, Brüning T, Eiriz I, Sántha P, Biverstål H, Jansone B, Haugen HJ, Krohn M, Pahnke J. Improved method for cannula fixation for long-term intracerebral brain infusion. J Neurosci Methods, 2017, 290, 145-50. https://doi.org/10.1016/j.jneumeth.2017.07.026
  • Steffen J, Krohn M, Schwitlick C, Brüning T, Paarmann K, Pietrzik CU, Biverstål H, Jansone B, Langer O, Pahnke J. Expression of endogenous mouse APP modulates β-amyloid deposition in hAPP-transgenic mice. Acta Neuropathol Commun, 2017, 5, 49. https://doi.org/10.1186/s40478-017-0448-2
  • Velena A, Zarkovic N, Klusa V, Klimaviciusa L, Pupure J, Vigante B, Duburs G. 1,4-Dihydropyridines as tools for mitochondrial medicine against oxidative stress and associated metabolic disorders. Curr Org Chem, 2017, 21(20), 2030-43. https://doi.org/10.1186/s40478-017-0448-2
  • Jansone B, Kadish I, van Groen T, Beitnere U, Plotniece A, Pajuste K, Klusa V. Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer’s disease transgenic female mice. Pharmacol Res, 2016, 113 (Pt B): 781-7. https://doi.org/10.1016/j.phrs.2016.06.020
  • Jansone B, Kuum M, Maciulaitis R. Introductory letter from the Presidents of the Latvian, Estonian and Lithuanian Societies of Pharmacology. Pharmacol Res, 2016, 113 (Pt B):721-2. http://doi.org/10.1016/j.phrs.2016.06.006
  • Jansone B, Kuum M, Maciulaitis R. Pharmacology in Estonia, Latvia and Lithuania: From historical roots to nowadays achievements. Pharmacol Res, 2016, 113 (Pt B):723-30. https://doi.org/10.1016/j.phrs.2016.04.024
  • Jansone B, Dzirkale Z, Jekabsons K, Pilipenko V, Beitnere U, Kletnieks U, Vanaga I, Muceniece R, Klusa V. Influence of spruce needle polyprenols on rat behavior and muscle tone altered by atorvastatin. Proc Latv Acad Sci, 2016, Sect B, 70(1).
  • Muceniece R, Namniece J, Nakurte I, Jekabsons K, Riekstina U, Jansone B. Pharmacological research on natural substances in Latvia: Focus on lunasin, betulin, polyprenol and phlorizin. Pharmacol Res, 2016, 113(Pt B), 760-70. https://doi.org/10.1016/j.phrs.2016.03.040
  • Jansone B, Kadish I, van Groen T, Beitnere U, Moore DR, Plotniece A, Pajuste K, Klusa V. A novel 1,4­-dihydropyridine derivative with memory ­improving activity in wild type and transgenic APPSweDI mice. Plos ONE, 2015, 10(6), e0127686. https://dx.doi.org/10.1371%2Fjournal.pone.0127686
  • Beitnere U, Dzirkale Z, Isajevs S, Rumaks J, Svirskis S, Klusa V. Carnitine congener mildronate protects against stress­ and haloperidol­ induced impairment in memory and brain protein expression in rats. Eur J Pharmacol, 2014, 745, 76­-83. https://doi.org/10.1016/j.ejphar.2014.10.014
  • Beitnere U, van Groen T, Kumar A, Jansone B, Klusa V, Kadish I. Mildronate improves cognition and reduces amyloid­-β pathology in transgenic Alzheimer’s disease mice. J Neurosci Res, 2014, 92(3), 338­-46. https://doi.org/10.1002/jnr.23315
  • Hägglund MG, Hellsten SV, Bagchi S, Ljungdahl A, Nilsson VC, Winnergren S, Stephansson O, Rumaks J, Svirskis S, Klusa V, Schiöth HB, Fredriksson R. Characterization of the transporter B0AT3 (Slc6a17) in the rodent central nervous system. BMC Neurosci, 2013, 14, 54. https://doi.org/10.1186/1471-2202-14-54
  • Klusa V, Beitnere U, Pupure J, Isajevs S, Rumaks J, Svirskis S, Dzirkale Z, Kalvinsh I. Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression. Medicina (Kaunas), 2013, 49(7), 301­-9. https://doi.org/10.3390/medicina49070047
  • Klusa V, Muceniece R, Isajevs S, Isajeva D, Beitnere U, Mandrika I, Pupure J, Rumaks J, Jansone B, Kalvinsh I, Vinters HV. Mildronate enhances learning/memory and changes hippocampal protein expression in trained rats. Pharmacol Biochem Behav, 2013, 106, 68-76. https://doi.org/10.1016/j.pbb.2013.03.012
  • Dzirkale Z, Rumaks J, Svirskis S, Mazina O, Allikalt A, Rinken A, Jekabsons K, Muceniece R, Klusa V. Lunasin­ induced behavioural effects in mice: Focus on the dopaminergic system. Behav Brain Res, 2013, 256, 5-9. https://doi.org/10.1016/j.bbr.2013.08.002
  • Rumaks J, Pupure J, Svirskis Š, Isajevs S, Duburs G, Kalvinsh I, Klusa V. Search for stroke-protecting agents in endothelin-1-induced ischemic stroke model in rats. Medicina (Kaunas), 2012, 48 (10), 525-­31. https://doi.org/10.3390/medicina48100077
  • Klimaviciusa L, Fernandes MAS, Lencberga N, Pavasare M, Vicente JAF, Moreno AJM, Santos MS, Oliveira CR, Bruvere I, Bisenieks E, Vigante B, Klusa V. Targeting the Mitochondria by Novel Adamantane-Containing 1,4-Dihydropyridine Compounds. Bioenergetics (Intech), 2012, 257-­72. https://doi.org/10.5772/32894
  • Sokolovska J, Rumaks J, Karajeva N, Grinvalde D, Sharipova J, Kluša V, Kalvinsh I, Sjakste N. The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rats with the streptozotocin model of diabetes mellitus. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2012, 6 (2), 177­-84. https://doi.org/10.18097/pbmc20115705490
  • Соколовска Е, Румакс Ю, Караева Н, Гринвалде Д, Клуша В, Калвиньш И, Сьяксте Н. Влияние милдроната на развитие периферической невропатии и некоторые показатели обмена глюкозы и липидов у крыс со стрептозотоциновой моделью сахарного диабета. Биомедицинская химия, 2011, 7(5), 490-­500.
  • Isajevs S, Svirina D, Beitnere U, Jansone B, Vinters HV, Kalvinsh I, Klusa V. Mildronate as a regulator of protein expression in a rat model of Parkinson’s disease. Medicina (Kaunas), 2011, 47(10), 552­-9. https://doi.org/10.3390/medicina47100079
  • Dzirkale Z, Pupure J, Rumaks J, Svirskis S, Vanina M, Mezhapuke R, Sile V, Fernandes MA, Duburs G, Klusa V. Comparative study of taurine and tauropyrone: GABA receptor binding, mitochondrial processes and behaviour. J Pharm Pharmacol, 2011, 63(2), 230­-7. https://doi.org/10.1111/j.2042-7158.2010.01204.x
  • Jekabsons K, Riekstina U, Parfejevs V, Laizane A, Pavasare M, Lencberga N, Jansone B, Muceniece R. Culture-expanded human dermal stem cells exhibit donor to donor differences in cAMP generation. Cell Tissue Res, 2011, 345(2), 253-63. http://doi.org/10.1007/s00441-011-1203-9
  • Klusa V, Isajevs S, Svirina D, Pupure J, Beitnere U, Rumaks J, Svirskis S, Jansone B, Dzirkale Z, Muceniece R, Kalvinsh I, Vinters HV. Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease. Int J Mol Sci, 2010, 11(11), 4465-­87. https://doi.org/10.3390/ijms11114465
  • Pupure J, Rumaks J, Isajevs S, Korzakova O, Puncule J, Svirskis S, Kalvinsh I, Klusa V. Mildronate’s protective effects in peripheral nervous system: stavudine ­induced neuropathy and formalin ­induced inflammation. Proc Latv Acad Sci, 2010, Sect B, 64, 3/4(668/669), 26–30.
  • Pupure J, Isajevs S, Kalvinsh I, Klusa V. Effects of mildronate in indinavir­ and efavirenz­ induced toxicity in mice. Proc Latv Acad Sci, 2010, Sect B, 64, 3/4(668/669), 20–25.
  • Pupure J, Isajevs S, Skapare E, Rumaks J, Svirskis S, Svirina D, Kalvinsh I, Klusa V. Neuroprotecive properties of mildronate, a mitochondria-­targeted small molecule. Neurosci Lett, 2010, 470(2), 100­-5. https://doi.org/10.1016/j.neulet.2009.12.055
  • Jansone B, Rumaks J, Pupure J, Dzirkale Z, Svirskis S, Muceniece R, Kluša V. γ1­ and γ2­ melanocyte stimulating hormones induce central anxiogenic effect and potentiate ethanol withdrawal responses in the elevated plus­ maze test in mice. Pharmacol Biochem Behav. 2009, 92(2), 267-71. https://doi.org/10.1016/j.pbb.2008.12.008
  • Pupure J, Isajevs S, Kratovska A, Gordjushina V, Taivans I, Rumaks J, Svirina D, Vīksna L, Kalvinš I, Kluša V. Mildronate protects from azidothymidine ­induced hepatotoxicity in mice liver. LU raksti (Medicīna), 2009, 750, 160-70.
  • Kluša V, Rumaks J, Karajeva N. Neuromidin attenuates neuropathic pain in the streptozocin ­induced diabetes model in rats. Proc Latv Acad Sci, 2008, Sect B, 62, 3(656), 20–30.
  • Sundberg BE, Wååg E, Jacobsson JA, Stephansson O, Rumaks J, Svirskis S, Alsiö J, Roman E, Ebendal T, Klusa V, Fredriksson R. The evolutionary history and tissue mapping of amino acid transporters belonging to solute carrier families SLC32, SLC36, and SLC38. J Mol Neurosci, 2008, 35(2), 179­-93. https://doi.org/10.1007/s12031-008-9046-x
  • Klimaviciusa L, Safiulina D, Kaasik A, Kluša V, Zharkovsky A. The effects of glutamate receptor antagonists on cerebellar granule cell survival and development. Neurotoxicol, 2008, 29(1):101-8. https://doi.org/10.1016/j.neuro.2007.09.006
  • Pupure J, Isajevs S, Gordjushina V, Taivans I, Rumaks J, Svirskis S, Kratovska A, Dzirkale Z, Pilipenko J, Duburs G, Klusa V. Distinct influence of atypical 1,4­dihydropyridine compounds in azidothymidine­ induced neuro- and cardiotoxicity in mice ex vivo. Basic Clin Pharmacol Toxicol, 2008, 103(5), 401­-6. https://doi.org/10.1111/j.1742-7843.2008.00221.x
  • Muceniece R, Saleniece K, Rumaks J, Krigere L, Dzirkale Z, Mezhapuke R, Zharkova O, Klusa V. Betulin binds to the γ­-aminobutyric acid receptors and exerts anticonvulsant action in mice. Pharmacol Biochem Behav, 2008, 90(4), 712­-6. https://doi.org/10.1016/j.pbb.2008.05.015
  • Muceniece R, Saleniece K, Krigere L, Rumaks J, Dzirkale Z, Mezhapuke R, Kviesis J, Mekss P, Klusa V, Schiöth HB, Dambrova M. Potato (Solanum tuberosum) juice exerts an anticonvulsant effect in mice through binding to GABA receptors. Planta Med, 2008, 74(5): 491­-6. https://doi.org/10.1055/s-2008-1074495
  • Pupure J, Fernandes MA, Santos MS, Moreno AJ, Kalvinsh I, Klusa V, Oliveira CR. Mitochondria as the target for mildronate’s protective effects in azidothymidine (AZT)­ induced toxicity of isolated rat liver mitochondria. Cell Biochem Funct, 2008, 26(5), 62­0-31. https://doi.org/10.1002/cbf.1486
  • Duburs G, Vigante B, Plotniece A, Krauze A, Sobolevs A, Briede J, Klusa V, Velena A. Dihydropyridine derivatives as bioprotectors. Chemistry Today, 2008, 26(2), 68-70.
  • Klimaviciusa L, Klusa V, Duburs G, Kaasik A, Kalda A, Zharkovsky A. Distinct effects of atypical 1,4-dihydropyridines on 1-methyl-4-phenylpyridinium-induced toxicity. Cell Biochem Funct, 2007, 25(1), 15­-21. https://doi.org/10.1002/cbf.1340
  • Isajevs S, Pupure J, Gordjushina V, Kratovska A, Taivans I, Vīksna L, Kalviņš I, Kluša V. Mildronate protects cardiotoxicity caused by stavudine and lamivudine. Proc Latv Acad Sci, 2007, Sect B, 6, 1/2(648/649), 26-­32.
  • Klimaviciusa L, Kalda A, Kaasik A, Zharkovsky A, Bisenieks E, Uldrikis J, Duburs G, Kluša V. Neuroprotective activity of 1,4-­dihydropyridine derivatives: structure determinants. Proc Latv Acad Sci, 2007, Sect B, 61, 1/2(648/649), 33-37.
  • Kluša V. Cerebrocrast (IOS-1.1212). Neuroprotectant, Cognition Enhancer. Autonomic & Autacoid Pharmacol, 2006, 26(1), 60-62.
  • Klusa V, Klimaviciusa L, Duburs G, Poikans J, Zharkovsky Q. Anti­neurotoxic effects of tauropyrone, a taurine analogue. Adv Exp Med Biol (Taurine 6: Taurine Update, KLUWER Publishers), 2006, 583, 499­-508.
  • Vicente JAF, Duburs G, Klusa V, Briede J, Klimaviciusa L, Zharkovsky A, Fernades MAS. Cerebrocrast as a neuroprotective, anti-diabetic and mitochondrial bioenergetic effector: a putative mechanism of action. Mitoch Pharmacol Toxicol (António J.M. Moreno, Editor), 2006, 37/661 (2), 185­-197.
  • Klusa V. Cerebrocrast, a cognition enhancer and neuroprotectant: focus on mitochondrial functions. Minireview, East­ European Symposium «Central and Peripheral Synaptic Transmission», dedicated to the 80th Anniversary of Prof. M. Papasova. Varna, Bulgaria. Minireview. Symposium Proc Auton Autacoid Pharmacol, 2006, 26, 60-2.
  • Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E. Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep, 2006, 58(4), 551-8.
  • Zvejniece L, Muceniece R, Krigere L, Dambrova M, Klusa VZ. The differential influences of melanocortins on nociception in the formalin and tail flick tests. Pharmacol Biochem Behav, 2006, 85(2), 287­-91. https://doi.org/10.1016/j.pbb.2006.08.001
  • Klusa V, Pupure J, Isajevs S, Rumaks J, Gordjushina V, Kratovska A, Taivans I, Svirskis S, Viksna L, Kalvinsh I. Protection of azidothymidine ­induced cardiopathology in mice by mildronate, a mitochondria ­targeted drug. Basic Clin Pharmacol Toxicol, 2006, 99(4), 323-­8. https://doi.org/10.1111/j.1742-7843.2006.pto_543.x
  • Klimavičiusa L, Kluša V, Duburs G, Kaasik A, Kalda A, Zharkovsky A. Neuroprotective (oxygen­glucose deprivation model) and neurotrophic effects of different 1,4-­dihydropyridine derivatives in cerebellar granule cells. Proc Latv Acad of Sci, 2005, Sect B, 59, 5(640), 169-174.
  • Krauze A, Vitoliņa R, Garaliene V, Sīle L, Kluša V, Duburs G. 3,4-trans-4-Aryl-3-(1-pyridinio)-1,2,3,4-tetrahydropyridine-6-thiolates--new group of potential cardiotonic drugs. Eur J Med Chem, 2005, 40(11), 1163­-7. https://doi.org/10.1016/j.ejmech.2005.04.004
  • Opmane B, Kluša V, Svirskis Š, Bergström L, Wikberg JES. The influence of γ1- and γ2-MSH on the rat dopaminergic mesolimbic system. In: Faculty of Medicine Scientific Papers (M. Pilmane, editor), 2001, IV (I), 631, 75-85.
  • Klimavičiusa L, Kluša V, Duburs, Kalda A, Zharkovsky A. Neuroprotective activity of a novel type of dihydropyridine derivatives in in vitro toxicity models. In: Faculty of Medicine Scientific Papers (M. Pilmane, editor), 2001, IV (I), 631, 55-64.
  • Semenova T, Anoshkina A, Fast A, Klusa V. Thyroliberin analogue reverses disturbances of behaviour and brain biogenic mine levels in antenatally hypoxised rats. Proc Latv Acad Sci, 2001, Sect B, 55, 23-9.
  • Klusa V, Germane S, Svirskis S, Opmane B, Wikberg JES. The g2-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors. Neuropeptides, 2001, 35(1), 50-7. https://doi.org/10.1054/npep.2000.0843
  • Kluša V, Gērmane, Noldner M, Chatterjee SS. Hypericum Extract and Hyperforin: memory enhancing properties. Pharmacopsychiatry, 2001, 34(1), S61-9. https://doi.org/10.1055/s-2001-15451
  • Kluša V. Bioethics in Latvia. Baltic Journal of Laboratory Animal Science, 2000, 10(3/4), 148-51.
  • Nevalainen T, Dontas I, Forslid A, Howard BR, Klusa V, Kasermann HP, Melloni E, Nebendahl K, Stafleu FR, Vergara P, Verstegen J. FELASA recommendations for the education and training of persons carrying out animal experiments (Category B). Report of the Federation of European Laboratory Animal Science Associations Working Group on Education of Persons Carryung out Animal Experiments (Category B) accepted by the FELASA Board of Management. Lab Anim, 2000, 34(3), 229-35. https://doi.org/10.1258/002367700780384672
  • Kluša V, Jacobson G. Ten years of Baltic Laboratory Animal Science Association. Baltic J Lab Anim Sci, 2000, 10, 5-6.
  • Opmane B, Kluša V, Svirskis Š, Bergström L, Wikberg JES. The influence of γ1- and γ2-MSH on the rat dopaminergic mesolimbic system. Acta Univ Latv, 2000, 65-75.
  • Devyatkina TA, Voloshina LI, Klusha VE. Cerebrocrast correction of reparative osteogenesis on the background of chronic stress. Fiziol Zhurn, 2000, 46, 36-40.
  • Klimavičiusa L, Kluša V, Duburs, Kalda A, Zharkovsky A. Neuroprotective activity of a novel type of dihydropyridine derivatives in in vitro toxicity models. Acta Univ Latv, 2000, 44-54.
  • Vazhnichaya EM, Devjatkina TA, Tarasenko LM, Klusha VE. [Correlation analysis of indices of non-specific resistance at aseptic inflammation and its correction with thymopentin]. Zhurn AMN Ukraini, 1999, 5(1), 136-48.
  • Kluša V, Svirskis Š, Ģērmane S, Opmane B, Muceniece R, Schiöth HB, Wikberg JES. Melanocortins and their receptors: behaviour and neurochemistry. Acta Univ Latv, 1999, 622, 155-63.
  • Liutkevičus E, Ulinskaite A, Meskys R, Kraujelis K, Duburs G, Kluša V. Influence of different types of the 1,4-dihydropyridine derivatives on rat plasma corticosterone levels. Biomed Lett, 1999, 60(234), 39-46.
  • Krauze A, Germane S, Eberlins O, Klusa V, Duburs G. Derivatives of 3-cyano-6-phenyl-4-(3`-pyridyl)-pyridine-2(1H)-thione and their neurotropic activity. Eur J Med Chem, 1999, 34(4), 301-10. https://doi.org/10.1016/S0223-5234(99)80081-6
  • Klusa V, Svirskis S, Opmane B, Wikberg JES, Muceniece R. Behavioural responses of the γ-MSH peptides administered into the rat ventral tegmental area. Acta Physiol Scand, 1999, 67, 99-104. https://doi.org/10.1046/j.1365-201x.1999.00595.x
  • Klusa V, Svirskis S, Opmane B, Skujins A, Muceniece R, Mutulis F, Wikberg JES, Schiöth HB. Evaluation of behavioural effects of neural melanocortin receptor antagonists injected ICV and intra VTA in rats. Neuropeptides, 1998, 32(6), 573-80. https://doi.org/10.1016/s0143-4179(98)90088-9
  • Misāne I, Kluša V, Dambrova M, Ģērmane S, Duburs G, Bisenieks E, Rimodini R, Ögren SO. “Atypical” neuromodulatory profile of glutapyrone, a representative of a novel “class” of amino acid-containing dipeptide-mimicking 1,4‐dihydropyridine (DHP) compounds: in vitro and in vivo studies. Eur Neuropsychopharmacol, 1998, 8(4), 329-47. https://doi.org/10.1016/s0924-977x(97)00097-7
  • Klusa V, Jākobsone G. Good scientific practice in the use of laboratory animals. Proc Latv Acad Sci, 1998, 52, 203-4.
  • Tarasenko LM, Neporada KS, Skriptnik IM, Klusha VE. Typological peculiarities of stress activation of peroxide oxidation of lipids and its correction by thymopentin. Fiziologichnij Zhurnal, 1997, 43, 113-6.
  • Poikāns J, Bisenieks E, Uldriķis J, Kluša V, Ģērmane S, Ģemme A, Duburs G. Octahydro derivatives of a novel heterocyclic system benzo[f][1,2] diazepino[5,4,3-c,d]indoles. Heterocyclic Communications, 1997, 3(1), 73-8. https://doi.org/10.1515/HC.1997.3.1.73
  • Velena A, Skujins A, Svirskis S, Bisenieks E, Uldriķis J, Poikāns J, Duburs G, Klusa V. Modification of swelling-contraction-aggregation processes in rat muscle mitochondria by the 1,4‐dihydropyridines, Cerebrocrast and Glutapyrone, themselves and in presence of azidothymidine. Cell Biochem Funct, 1997, 15(3), 211-20. https://doi.org/10.1002/(SICI)1099-0844(199709)15:3%3C211::AID-CBF743%3E3.0.CO;2-L
  • Klusa V, Vītolina R, Dambrova M, Atare Z, Mežapuke R, Meirena D, Bisenieks E, Duburs G, Azzi A. The effects of glutapyrone, a glutamate-containing 1,4- dihydropyridine, on the cardiovascular system, smooth muscle contraction, and protein kinase C activities. Proc Latv Acad Sci, B. 1996, 50, 108-13.
  • Klusa V, Germane S. Alcoholized maternal rat offspring: model for testing of physical and psychoemotional neurodeficit. Scand J Lab Animal Sci, 1996, 23, 403-9.
  • Schiöth HB, Chhajlani V, Muceniece R, Kluša V, Wikberg JES. Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci, 1996, 59(10), 797-812. https://doi.org/10.1016/0024-3205(96)00370-0
  • Klusa V, Duburs G. Cognition enhancers (Nootropic drugs). Review. Acta Medica Baltica. 1996, 3, 104-14.
  • Ģērmane S, Misāne I, Kluša V. Alcohol-induced accelerated aging in mice: a convenient model for testing the normalizing influence of cerebrocrast on the altered CNS functioning. Laboratornye Zhivotnye, 1995, 5, 73-81.
  • Mutulis F, Mutule I, Ģērmane S, Kluša V, Mishlyakova NV, Rhaleb NE, Regoli D. Cyclic analogues of Bradykinin. Review. Proc Latv Acad Sci, 1993, 1, 49-53.
  • Kluša V, Ģērmane S, Muceniece R, Liepa I, Dambrova M, Svirskis Š, Sīle V, Kublis G. Facilitating influence of thymopentin on learning: behaviour and neurochemical data. Proc Latv Acad Sci, 1993, 8, 56-9.
  • Misāne I, Cēbers G, Liepa I, Dambrova M, Ģērmane S, Kluša V, Duburs G, Bisenieks E. Cyclic nootropics: similarity and differences in their memory improving action. Proc Latv Acad Sci, 1993, 5, 81-5.
  • Karpova MN, Pankov OY, Ģērmane SK, Kluša VE, Duburs GY. Antiepileptic effects of glutapyrone, a novel derivative of 1,4-dihydropyridine, administered in combination with sodium valproate and phenobarbital. Bull Exp Biol Med, 1993, 116(6), 1482-5. http://dx.doi.org/10.1007/BF00785477
  • Karpova MN, Ģērmane SK, Pankov OY, Kluša VE, Duburs GY. Effects of glutapyrone, a new amino acid-containing 1,4-dihydropyridine, on focal penicillin-induced epileptic activity and on bicuculline- or thiosemicarbazide-induced convulsions. Bull Exp Biol Med, 1993, 116(10), 357-60. http://dx.doi.org/10.1007/BF00802832
  • Karpova MN, Ģērmane SK, Tsebers G, Pankov OY, Klusha VE, Dubur GY, Bisenieks EA. Anticonvulsive activity of glutapyrone, a new type of derivative of amino acid-containing 1,4‐dihydropyridine. Bull Exp Biol Med, 1993, 116(3), 1119-21. http://dx.doi.org/10.1007/BF00820235
  • Kluša V, Duburs G, Ģērmane S, Muceniece R, Cēbers G, Misāne I, Bisenieks E, Liepa I, Dambrova M. Structure and activity peculiarities of Cerebrocrast (IOS-1.1212), a novel type of CNS-modulating 1,4-dihydropyridines. Proc Latv Acad Sci, 1992, Sect B, 9, 51-5.
  • Kluša V. Cerebrocrast (IOS-1.1212) - a novel brain function enhancer (Introduction). Proc Latv Acad Sci, 1992, 9, 49-50.
  • Kluša V, Ģērmane S, Muceniece R, Rakauskaite I, Liepa I, Dambrova M, Duburs G, Misāne I. Neuroregulatory properties of 1,4-dihydropyridines (DHP). - In: Pharmacology of Novel centrally and Peripherally Acting Drugs. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1991, 38-9.
  • Porozovs Y, Vorobieva L, Dundure B, Jerusalimsky A, Kluša V. Preventive potency of neuropeptides against electrostatic field (ESF)-induced neurochemical and behavioural alterations. - In: Pharmacology Novel centrally and Peripherally Acting Drugs. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1991, 139-59.
  • Porozovs Y, Vorobieva L, Dundure B, Jerusalimsky A, Kluša V. Neuropeptides protect the electrostatic field-induced alterations in the brain mitochondrial adenosine triphosphate activities. - In: Pharmacology of Novel centrally and Peripherally Acting Drugs. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1991, 55-6.
  • Mishlyakova N, Strazda G, Kluša V, Mutulis F, Mutule I, Maurops G, Chipens G. Investigation of biological activity and action specificity of the cyclic analogues of substance P. - In: Central and Peripheral Peptidergic Regulation. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1991, 35-40.
  • Svirskis Š, Muceniece R, Kluša V, Ancāns J, Georgiev V, Getova O. Angiotensin and its analogues: comparative studies of their central effects. - In: Central and Peripheral Peptidergic Regulation. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1991, 120-8.
  • Muceniece R, Liepa I, Skliarova S, Gnilomedova L, Rudziš R, Kudryavcev O, Kluša V. Modulation of immunization-induced changes in the immune and central nervous systems by short immune protein fragments. - In: Central and Peripheral Peptidergic Regulation. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1991, 129-38.
  • Ģērmane S, Bleidelis E, Rakauskaite I, Kluša V. Neuropharmacological study of IOS-1.1212, a novel dihydropyridine derivative. Latv ZA Vestis, 1991, 2, 112-24.
  • Klusa V, Kiivet R-A, Muceniece R, Liepa I, Harro J, Svirskis S, Andermanis A, Rago L. Thymopentin antagonizes stress-induced changes of GABA/benzodiazepine receptor complex. Regul Pept, 1990, 27(3), 355-65. https://doi.org/10.1016/0167-0115(90)90124-f
  • Ieviņa N, Kluša V. Integrational mechanisms involved in the regulatory functions of the central nervous and immune systems. - In: Thymopentin: A Novel Regulatory Neuropeptide. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1990, 7-34.
  • Kluša V, Muceniece R, Liepa I, Svirskis Š, Andermanis A, Zālītis G, Rituma I, Szabo G, Telegdy G, Rago L, Kiivet R-A, Allikmets L. Regulatory properties of thymopentin. - In: Thymopentin: A Novel Regulatory Neuropeptide. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1990, 35-62.
  • Vorobieva LF, Porozov YM, Kluša V, Ierusalimsky AP. The use of thymopentin for reversing disbalance of the rat brain monoamine systems caused by exposure to electrostatic fields. - In: Thymopentin: a Novel Regulatory Neuropeptide. - Riga: Inst. of Organic Synthesis, Latv Acad Sci, 1990, 125-38.
  • Kluša V, Muceniece R, Svirskis S, Kukaine E, Ratkevica M, Rosenthal G, Afanasyeva G. Involvement of non-opiate peptides in psychoneuroimmunological modulations - In: Enkephalins and Endorphins: Stress and the Immune System. Eds. N. P. Plotnikoff, R. E. Faith, A. J. Murgo, R. A. Good. N.Y.; London: Plenum Press, 1986, 145-57.
  • Valdman AV, Kozlovskaya MM, Bondarenko NA, Rojanetz VV, Avdulov NA, Klusha VE, Muceniece RK. Monoaminergic mechanisms of psychotropic action of short peptides - In: Drug Dependence and Emotional Behavior: Neurophysiol. and Neurochem. Approaches. New York; London: Consultants Bureau, 1986, 203-38.
  • Chipens GI, Mutulis FK, Mishlyakova NV, Misina IP, Vitolina RO, Klusha VJ, Katayev V. Cyclic analogues of bradykinin IV. Structure-function relationships in a series of cyclic analogues of bradykinin. Internat J Peptide Protein Research, 1985, 26(5), 460-8. http://dx.doi.org/10.1111/j.1399-3011.1985.tb01013.x